Until recently,
vitamin K antagonists were the only available oral
anticoagulants, but with numerous limitations that prompted the introduction of new oral
anticoagulants targeting the single coagulation
enzymes thrombin (
dabigatran) or
factor Xa (
apixaban,
rivaroxaban, and
edoxaban) and given in fixed doses without coagulation monitoring. Here we review the pharmacology and the results of clinical trials with these new agents in
stroke prevention in
atrial fibrillation and
secondary prevention after
acute coronary syndromes, providing perspectives on their future incorporation into clinical practice. In phase III trials in
atrial fibrillation, compared with
warfarin,
dabigatran etexilate 150 mg B.I.D. reduced the rates of
stroke/systemic
embolism without any difference in major
bleeding;
dabigatran etexilate 110 mg B.I.D. had similar efficacy with decreased
bleeding;
apixaban 5 mg B.I.D. reduced
stroke, systemic
embolism, and mortality as well as major
bleeding; and
rivaroxaban 20 mg Q.D. was noninferior to
warfarin for
stroke and systemic
embolism without a difference in major
bleeding. All these agents reduced
intracranial hemorrhage.
Edoxaban is currently being evaluated in a further large phase III trial.
Apixaban and
rivaroxaban were evaluated in phase III trials for prevention of recurrent
ischemia in patients with
acute coronary syndromes who were mostly receiving dual antiplatelet
therapy, with conflicting results on efficacy but consistent results for increased major
bleeding. Overall, the new oral
anticoagulants are poised to replace
vitamin K antagonists for many patients with
atrial fibrillation and may have a role after
acute coronary syndromes. Although convenient to administer and manage, they present challenges that need to be addressed.